An Intermediate Expanded Use Trial of DFMO

Exclusion Criteria

• •2. Medulloblastoma patients who have completed standard of care therapies.
• •3. Relapsed/refractory neuroblastoma patients who have completed standard of care therapies.
• •4. Rare tumors with increased LIN28 expression or MYCN amplification or up regulation of ornithine decarboxylase who have completed standard of care therapies.
• •A negative serum or urine pregnancy test is required for female subjects of child bearing potential (onset of menses or ≥13 years of age).
• •Both male and female post-pubertal study subjects need to agree to use one of the more effective birth control methods during treatment and for six months after treatment is stopped. These methods include total abstinence (no sex), oral contraceptives ("the pill"), an intrauterine device (IUD), levonorgestrol implants (Norplant), or medroxyprogesterone acetate injections (Depo-provera shots). If one of these cannot be used, contraceptive foam with a condom is recommended.
• •Informed Consent: All subjects and/or legal guardians must sign informed written consent. Assent, when appropriate, will be obtained according to institutional guidelines
• •BSA (m2) of \<0.25
• •Investigational Drugs: Subjects who are currently receiving another investigational drug are excluded from participation.